308.31
price up icon2.74%   +8.23
 
loading
Icon Plc stock is currently priced at $308.31, with a 24-hour trading volume of 714.48K. It has seen a +2.74% increased in the last 24 hours and a -6.55% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $305.1 pivot point. If it approaches the $313.5 resistance level, significant changes may occur.
Previous Close:
$300.08
Open:
$302.85
24h Volume:
714.48K
Market Cap:
$25.49B
Revenue:
$8.23B
Net Income/Loss:
$683.12M
P/E Ratio:
49.73
EPS:
6.2
Net Cash Flow:
$1.17B
1W Performance:
+6.97%
1M Performance:
-6.55%
6M Performance:
+28.16%
1Y Performance:
+53.48%
1D Range:
Value
$300.25
$310.41
52W Range:
Value
$181.92
$344.77

Icon Plc Stock (ICLR) Company Profile

Name
Name
Icon Plc
Name
Phone
353 1 291 2000
Name
Address
South County Business Park, Leopardstown, Dublin
Name
Employee
13,620
Name
Twitter
@ICONplc
Name
Next Earnings Date
2024-04-25
Name
Latest SEC Filings
Name
ICLR's Discussions on Twitter

Icon Plc Stock (ICLR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-15-23 Initiated Truist Buy
Sep-13-23 Initiated TD Cowen Outperform
Jan-17-23 Upgrade Barclays Equal Weight → Overweight
Jan-13-23 Upgrade Barclays Equal Weight → Overweight
Nov-09-22 Upgrade BofA Securities Neutral → Buy
Sep-07-22 Initiated UBS Buy
Aug-25-22 Initiated Credit Suisse Neutral
May-24-22 Initiated Guggenheim Buy
Apr-25-22 Downgrade Wells Fargo Overweight → Equal Weight
Apr-12-22 Upgrade Deutsche Bank Hold → Buy
Sep-27-21 Upgrade JP Morgan Neutral → Overweight
Aug-05-21 Resumed Credit Suisse Outperform
Jul-23-21 Upgrade Citigroup Neutral → Buy
Jul-14-21 Initiated Citigroup Neutral
Apr-13-21 Resumed BofA Securities Neutral
Apr-01-21 Upgrade Wells Fargo Equal Weight → Overweight
Mar-08-21 Upgrade Robert W. Baird Neutral → Outperform
Mar-03-21 Initiated Barclays Equal Weight
Mar-01-21 Upgrade UBS Neutral → Buy
Feb-26-21 Upgrade Truist Hold → Buy
Jul-24-20 Downgrade BofA Securities Buy → Neutral
Apr-20-20 Downgrade Robert W. Baird Outperform → Neutral
Mar-26-20 Upgrade Barclays Equal Weight → Overweight
Mar-02-20 Initiated Deutsche Bank Hold
Jan-27-20 Downgrade SunTrust Buy → Hold
Jan-08-20 Initiated Wells Fargo Equal Weight
Jan-07-20 Initiated Citigroup Neutral
Sep-23-19 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jul-26-19 Upgrade UBS Sell → Neutral
Jan-25-19 Upgrade Mizuho Neutral → Buy
Oct-26-18 Upgrade Evercore ISI In-line → Outperform
Oct-09-18 Initiated UBS Sell
Apr-03-18 Downgrade Evercore ISI Outperform → In-line
Feb-15-18 Reiterated Mizuho Neutral
Jan-19-18 Initiated Evercore ISI Outperform
Oct-27-17 Reiterated Barclays Equal Weight
Sep-11-17 Initiated BofA/Merrill Buy
Jul-31-17 Upgrade SunTrust Hold → Buy
Jul-27-17 Reiterated Mizuho Neutral
Jun-29-17 Upgrade Jefferies Hold → Buy
View All

Icon Plc Stock (ICLR) Financials Data

Icon Plc (ICLR) Revenue 2024

ICLR reported a revenue (TTM) of $8.23 billion for the quarter ending March 31, 2024, a +5.29% rise year-over-year.
loading

Icon Plc (ICLR) Net Income 2024

ICLR net income (TTM) was $683.12 million for the quarter ending March 31, 2024, a +33.95% increase year-over-year.
loading

Icon Plc (ICLR) Cash Flow 2024

ICLR recorded a free cash flow (TTM) of $1.17 billion for the quarter ending March 31, 2024, a +223.06% increase year-over-year.
loading

Icon Plc (ICLR) Earnings per Share 2024

ICLR earnings per share (TTM) was $8.22 for the quarter ending March 31, 2024, a +33.01% growth year-over-year.
loading
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.
diagnostics_research MTD
$1,238.09
price up icon 0.42%
$122.28
price up icon 1.02%
diagnostics_research WAT
$311.30
price up icon 0.96%
diagnostics_research LH
$198.40
price up icon 0.03%
diagnostics_research A
$137.74
price up icon 1.00%
Cap:     |  Volume (24h):